FDA backs CAD-1005 Phase 3 HIT trial path at Cadrenal (NASDAQ: CVKD)
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cadrenal Therapeutics announced that it successfully completed its End-of-Phase 2 meeting with the FDA and received guidance for a pivotal Phase 3 trial of CAD-1005 in heparin-induced thrombocytopenia (HIT). Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.
The company plans a randomized, blinded, placebo-controlled Phase 3 study in approximately 120 HIT patients across up to 50 clinical centers worldwide, with treatment for up to 14 days during hospitalization. The trial is intended to support a projected NDA submission in 2029.
Positive
- Regulatory inflection point for CAD-1005: Successful End-of-Phase 2 FDA meeting with clear guidance for a randomized, blinded, placebo-controlled Phase 3 registration trial in HIT, intended to support a projected NDA submission in 2029.
Negative
- None.
Insights
FDA End-of-Phase 2 guidance sets a defined pivotal Phase 3 path for CAD-1005 in HIT.
Cadrenal Therapeutics reports a major regulatory milestone: a successful End-of-Phase 2 meeting with the FDA for CAD-1005, its first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia. The agency provided detailed input on protocol design, population, dosing, background therapy, safety database and the primary thrombotic endpoint.
Phase 2 results showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy, which supports moving directly into a pivotal trial. The planned Phase 3 will randomize about 120 patients across up to 50 global centers, with standard-of-care anticoagulation plus CAD-1005 or placebo.
The study is intended to underpin a projected NDA submission in 2029, and would be the first randomized, blinded, placebo-controlled registration trial in HIT. CAD-1005 already has Orphan Drug and Fast Track designations, which can facilitate development. Actual impact will depend on Phase 3 execution, funding, and whether the thrombotic benefit and safety profile are confirmed at scale.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Phase 2 thrombotic event reduction: greater than 25% absolute reduction
Planned Phase 3 enrollment: approximately 120 patients
Planned Phase 3 sites: up to 50 clinical centers
+4 more
7 metrics
Phase 2 thrombotic event reduction
greater than 25% absolute reduction
Thrombotic events when CAD-1005 was added to standard anticoagulant therapy
Planned Phase 3 enrollment
approximately 120 patients
Pivotal randomized, blinded, placebo-controlled HIT trial
Planned Phase 3 sites
up to 50 clinical centers
Global sites for pivotal CAD-1005 HIT study
Treatment duration
up to 14 days
In-hospital treatment period in planned Phase 3 HIT trial
Projected NDA timing
2029
Pivotal Phase 3 study intended to support NDA submission
Annual U.S. heparin patients
more than 12 million patients
Heparin use in the United States each year
HIT mortality rate
exceeding 20%
Mortality rates for HIT in some studies
Key Terms
End-of-Phase 2 (EOP2) meeting, 12-lipoxygenase (12-LOX) inhibitor, heparin-induced thrombocytopenia (HIT), Orphan Drug Designation (ODD), +2 more
6 terms
End-of-Phase 2 (EOP2) meeting regulatory
"announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting"
An end-of-phase 2 (EoP2) meeting is a formal discussion between a drug developer and regulators to review mid-stage clinical results and agree on the design, size and success measures of the pivotal Phase 3 trials needed for approval. For investors, the meeting is like a road-test report with a traffic plan: a favorable outcome reduces uncertainty about whether the program can reach approval, shortens timelines and clarifies likely costs and risks.
12-lipoxygenase (12-LOX) inhibitor medical
"CAD-1005, the Company’s investigational first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia"
A 12-lipoxygenase (12-LOX) inhibitor is a drug that blocks the action of the 12-LOX enzyme, which helps produce molecules that drive inflammation, blood‑clotting and certain disease processes. For investors, these inhibitors matter because they represent a targeted therapy approach—like stopping a single machine on a factory line to reduce harmful output—potentially treating conditions such as inflammatory diseases, clotting disorders or some cancers, and therefore carrying clinical, regulatory and commercial value if proven safe and effective.
heparin-induced thrombocytopenia (HIT) medical
"CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) FDA provided critical guidance"
Heparin-induced thrombocytopenia (HIT) is a serious immune reaction to the blood thinner heparin where the body mistakenly attacks platelets, causing their count to fall while paradoxically increasing the risk of dangerous clots; think of it as a friendly-fire response that both reduces clot-control cells and sparks unwanted clots. For investors, HIT matters because it can change demand for safer alternatives, trigger product warnings or sales restrictions, increase treatment costs, and raise regulatory and legal risks for drugmakers and hospitals.
Orphan Drug Designation (ODD) regulatory
"CAD-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the U.S."
Orphan drug designation (ODD) is a regulatory status granted to a medicine intended to treat a rare disease or condition, giving the developer special incentives such as reduced fees, development support, and a period of exclusive market rights. For investors, ODD signals that a product may face less competition, enjoy stronger pricing power, and benefit from lower development costs and regulatory help—similar to receiving a temporary protected license to serve a small but underserved market.
Fast Track designation regulatory
"CAD-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the U.S."
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
Serotonin Release Assay (SRA) medical
"incidence of new or worsening thrombotic events in patients with Serotonin Release Assay (SRA)-confirmed HIT"
A serotonin release assay (SRA) is a specialized laboratory test that detects whether a patient’s blood contains antibodies that activate platelets to release serotonin, a sign of a dangerous immune reaction often associated with certain anticoagulant drugs. For investors, an SRA result can influence clinical use, regulatory decisions, product labeling, and liability — like a smoke detector confirming a real fire versus a false alarm, it helps determine whether a safety concern is genuine and requires action.
FAQ
What did Cadrenal Therapeutics (CVKD) announce regarding CAD-1005 and the FDA?
Cadrenal Therapeutics reported a successful End-of-Phase 2 meeting with the FDA for CAD-1005 in HIT. The agency provided guidance on protocol design, dosing, safety database, and endpoints, supporting plans for a pivotal Phase 3 trial as a registration pathway.
How did CAD-1005 perform in Phase 2 for heparin-induced thrombocytopenia?
In Phase 2, CAD-1005 showed a greater than 25% absolute reduction in thrombotic events when added to standard anticoagulant therapy. This improvement in clot-related outcomes underpins Cadrenal’s decision to proceed directly to a randomized, blinded, placebo-controlled Phase 3 study in HIT.
What is the planned design of Cadrenal Therapeutics’ Phase 3 HIT trial?
The planned pivotal Phase 3 trial will randomize approximately 120 patients with suspected HIT to CAD-1005 or placebo plus standard-of-care anticoagulants. It will run across up to 50 centers worldwide, with up to 14 days of in-hospital treatment and a centrally adjudicated thrombotic endpoint.
When could CAD-1005 potentially reach an NDA filing according to Cadrenal (CVKD)?
Cadrenal states the pivotal Phase 3 trial of CAD-1005 in HIT is intended to support a projected NDA submission in 2029. That timing assumes successful completion of the randomized, blinded, placebo-controlled study and adequate safety and efficacy data in the target patient population.
Does CAD-1005 have any special regulatory designations for HIT?
CAD-1005 has received Orphan Drug Designation and Fast Track designation from the U.S. FDA for HIT, plus orphan status from the European Medicines Agency. These designations can offer incentives such as development support and potential regulatory efficiencies for rare, serious conditions.
How common and serious is heparin-induced thrombocytopenia according to Cadrenal?
The company notes more than 12 million U.S. patients receive heparin annually, and HIT is a life-threatening immune complication. It can cause widespread clotting, low platelets, and bleeding, with complications like stroke and pulmonary embolism, and mortality reported above 20% in some studies.